The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

St. Jude receives $2 million pledge from InfinityQS International Inc.

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

ST. JUDE CHILDREN’S RESEARCH HOSPITAL received a pledge of $2 million over the next 10 years from InfinityQS International Inc.

St. Jude has named the Large Auditorium Gathering Space in the Marlo Thomas Center for Global Education and Collaboration in honor of InfinityQS to commemorate the company’s support.

InfinityQS received the Cardinal Stritch Donor of the Year Award, which recognizes a donor whose commitment reflects the vision and leadership of St. Jude founder Danny Thomas’ spiritual mentor, Samuel Cardinal Stritch, the Catholic archbishop of Chicago. InfinityQS has also sponsored and participated as St. Jude Heroes in three of the hospital’s annual St. Jude Memphis Marathon Weekend fundraisers.

Table of Contents

YOU MAY BE INTERESTED IN

Regulatory News

Makary vows to speed up drug approvals and end FDA’s “cozy” relationship with industry
Commissioner promises to protect scientific integrity while bringing in “fresh” MAHA ideas

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
By Claire Marie Porter
Guest Editorial

Regulation must keep up with scientific advances

The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.
By Richard M. Goldberg
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account